Research & Literature

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.

Ackerman S, Smith LM, Gomes PJ

Therapeutic advances in chronic disease 2016; (7(1)):52-67 doi:10.1177/2040622315612745.

The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases.

Fujishima H, Okada N, Matsumoto K, et al.

The Journal of allergy and clinical immunology 2016; (138(2)):459-467.e2.

Clinical Usefulness of Monitoring Expression Levels of CCL24 (Eotaxin-2) mRNA on the Ocular Surface in Patients with Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis.

Shiraki Y, Shoji J, Inada N

Journal of ophthalmology 2016; (2016()):3573142 doi:10.1155/2016/3573142.

Atopic keratoconjunctivitis: long-term results of medical treatment and penetrating keratoplasty.

Koçluk Y, Yalniz-Akkaya Z, Burcu A, Örnek F

Arquivos brasileiros de oftalmologia 2016; (79(6)):376-379 doi:10.5935/0004-2749.20160107.

Surgical outcomes of perforated and unperforated corneal descemetocele.

Ozdemir ES, Burcu A, Akkaya ZY, Ornek F

International ophthalmology 2018; (38(1)):327-335 doi:10.1007/s10792-017-0472-z.

Histamine H1 and H4 receptor expression on the ocular surface of patients with chronic allergic conjunctival diseases.

Inada N, Shoji J, Shiraki Y, et al.

Allergology international : official journal of the Japanese Society of Allergology 2017; (66(4)):586-593 doi:10.1016/j.alit.2017.03.004.

Amniotic membrane transplantation: Current indications in a tertiary eye hospital of eastern Nepal.

Hamal D, Singh SK, Lamichhane B, et al.

Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2016; (8(16)):151-160 doi:10.3126/nepjoph.v8i2.17004.

Atopic keratoconjunctivitis with corneal ulcer. Case report.

Zemba M, Burcea M, Camburu G

Romanian journal of ophthalmology 2016; (60(3)):200-206.

Allergic conjunctivitis: current concepts on pathogenesis and management.

Sacchetti M, Abicca I, Bruscolini A, et al.

Journal of biological regulators and homeostatic agents 2018; (32(1 Suppl. 1)):49-60.

Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review.

Li J, Luo X, Ke H, Liang L

Pediatrics 2018; (141(Suppl 5)):S470-S474 doi:10.1542/peds.2016-2069.

Atopic keratoconjunctivitis: A diagnostic dilemma-a case report.

Li A, Li S, Ruan F, Jie Y

Medicine 2018; (97(16)):e0372 doi:10.1097/MD.0000000000010372.

Immunopathological Features of Severe Chronic Atopic Keratoconjunctivitis and Effects of Topical Cyclosporine Treatment.

Utine CA, Stern M, Akpek EK

Ocular immunology and inflammation 2019; (27(7)):1184-1193 doi:10.1080/09273948.2018.1511811.

Transcriptome profiling of refractory atopic keratoconjunctivitis by RNA sequencing.

Matsuda A, Asada Y, Suita N, et al.

The Journal of allergy and clinical immunology 2019; (143(4)):1610-1614.e6 doi:10.1016/j.jaci.2018.11.007.

Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis.

Jabbehdari S, Starnes TW, Kurji KH, et al.

The ocular surface 2019; (17(2)):303-309 doi:10.1016/j.jtos.2018.12.002.

The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis.

Yazu H, Shimizu E, Aketa N, et al.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2019; (122(4)):387-392.e1 doi:10.1016/j.anai.2019.01.004.

Emerging Therapeutics for Ocular Surface Disease.

Bielory L, Schoenberg D

Current allergy and asthma reports 2019; (19(3)):16 doi:10.1007/s11882-019-0844-8.

Tacrolimus ointment in the management of atopic keratoconjunctivitis.

Benaim D, Tétart F, Bauvin O, et al.

Journal francais d'ophtalmologie 2019; (42(4)):e147-e151 doi:10.1016/j.jfo.2019.02.003.

Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Ridolo E, Kihlgren P, Pellicelli I, et al.

Drugs & aging 2019; (36(7)):581-588 doi:10.1007/s40266-019-00676-7.

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.

Thyssen JP, de Bruin-Weller MS, Paller AS, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(7)):1224-1231 doi:10.1111/jdv.15608.

Topical tacrolimus for allergic eye diseases.

Erdinest N, Ben-Eli H, Solomon A

Current opinion in allergy and clinical immunology 2019; (19(5)):535-543 doi:10.1097/ACI.0000000000000560.

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.

Maudinet A, Law-Koune S, Duretz C, et al.

Ophthalmology and therapy 2019; (8(3)):485-490 doi:10.1007/s40123-019-0191-9.

Epidemiological Association Between Systemic Diseases and Keratoconus in a Korean Population: A 10-Year Nationwide Cohort Study.

Lee HK, Jung EH, Cho BJ

Cornea 2020; (39(3)):348-353 doi:10.1097/ICO.0000000000002206.

Air pollution significantly associated with severe ocular allergic inflammatory diseases.

Miyazaki D, Fukagawa K, Fukushima A, et al.

Scientific reports 2019; (9(1)):18205 doi:10.1038/s41598-019-54841-4.

Association between atopic keratoconjunctivitis and the risk of keratoconus.

Weng SF, Jan RL, Wang JJ, et al.

Acta ophthalmologica 2021; (99(1)):e54-e61 doi:10.1111/aos.14509.

Pharmacotherapeutic management of atopic keratoconjunctivitis.

Hossain IT, Sanghi P, Manzouri B

Expert opinion on pharmacotherapy 2020; (21(14)):1761-1769 doi:10.1080/14656566.2020.1786534.

Association between atopic keratoconjunctivitis and the risk of corneal ulcer.

Jan RL, Weng SF, Wang JJ, et al.

The British journal of ophthalmology 2021; (105(12)):1632-1637 doi:10.1136/bjophthalmol-2020-316206.

Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years.

Kim SE, Nowak V, Quartilho A, et al.

The Cochrane database of systematic reviews 2020; (10()):CD013298 doi:10.1002/14651858.CD013298.pub2.

IL-1α antibody inhibits dose-dependent exacerbation of eosinophilic inflammation by crude house-dust-mite antigen in the conjunctiva of an atopic keratoconjunctivitis mouse model.

Shiraki Y, Shoji J, Inada N, et al.

Current eye research 2021; (46(8)):1115-1124 doi:10.1080/02713683.2021.1874022.

Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases.

Yazu H, Fukagawa K, Shimizu E, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2021; (17(1)):11 doi:10.1186/s13223-021-00513-w.

Current Knowledge in Allergic Conjunctivitis.

Villegas BV, Benitez-Del-Castillo JM

Turkish journal of ophthalmology 2021; (51(1)):45-54 doi:10.4274/tjo.galenos.2020.11456.

Glycomics in tears: seeking for new biomarkers for ocular allergy diagnosis.

Fauquert JL, Kowalski ML

Allergy 2021; (76(8)):2335-2336 doi:10.1111/all.14846.

Traffic-related particulate matter aggravates ocular allergic inflammation by mediating dendritic cell maturation.

Hwang M, Han S, Seo JW, et al.

Journal of toxicology and environmental health. Part A 2021; (84(16)):661-673 doi:10.1080/15287394.2021.1922111.

Association of Allergic Conjunctivitis With Health-Related Quality of Life in Children and Their Parents.

Zhang SY, Li J, Liu R, et al.

JAMA ophthalmology 2021; (139(8)):830-837 doi:10.1001/jamaophthalmol.2021.1708.

Association Between Atopic Keratoconjunctivitis and the Risk of Recurrent Corneal Erosion.

Jan RL, Weng SF, Wang JJ, et al.

Frontiers in medicine 2021; (8()):688355 doi:10.3389/fmed.2021.688355.

Severe allergic eye disease: What to do and when?

Dahlmann-Noor A, Muthusamy K, Hingorani M

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2021; (51(8)):989-991 doi:10.1111/cea.13985.

Difference in the plasma level of miR-628-3p in atopic dermatitis patients with/without atopic keratoconjunctivitis.

Ueta M, Nishigaki H, Komai S, et al.

Immunity, inflammation and disease 2021; (9(4)):1815-1819 doi:10.1002/iid3.536.

Evaluation of Clinical Efficacy and Safety of Prolonged Treatment of Vernal and Atopic Keratoconjunctivitis Using Topical Tacrolimus.

Hirota A, Shoji J, Inada N, et al.

Cornea 2022; (41(1)):23-30 doi:10.1097/ICO.0000000000002692.

Importance of Corneal Angiography in Subclinical Limbitis in a Case of Atopic Keratoconjunctivitis.

Romano D, Coco G, Borgia A, et al.

Cornea 2022; (41(8)):1038-1040 doi:10.1097/ICO.0000000000002891.

Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.

Foley P, Kerdraon YA, Hogden JP, et al.

The Australasian journal of dermatology 2022; (63(4)):421-436 doi:10.1111/ajd.13924.

Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.

Adachi R, Shoji J, Hirota A, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):89 doi:10.1186/s13223-022-00727-6.

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab-Associated Conjunctivitis in Patients with Atopic Dermatitis.

Patra V, Woltsche N, Cerpes U, et al.

Ophthalmology science 2024; (4(1)):100340 doi:10.1016/j.xops.2023.100340.

Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report.

Galluzzo M, Tofani L, Spelta S, et al.

Skin health and disease 2024; (4(3)):e354 doi:10.1002/ski2.354.

Where eye meets body part 2: uniting allergy pathways in ocular and atopic disease - T cells take the lead.

Borges S, Pereira VA, Chang C, Galor A

Current opinion in allergy and clinical immunology 2025; (25(5)):364-373 doi:10.1097/ACI.0000000000001097.

Emerging concepts in atopic dermatitis and atopic keratoconjunctivitis.

Jafari K, Calder VL

Current opinion in allergy and clinical immunology 2025; (25(5)):388-394 doi:10.1097/ACI.0000000000001102.

Periostin promotes inflammation and neovascularization in atopic keratoconjunctivitis.

Nunomura S, Nanri Y, Honda Y, et al.

The Journal of allergy and clinical immunology 2026; (157(2)):387-397 doi:10.1016/j.jaci.2025.10.004.

Janus kinase inhibitors are effective in atopic keratoconjunctivitis treatment and not only in managing dupilumab-induced ocular adverse events.

Bendoukha Y, Jacob B, Muraine M, et al.

The British journal of dermatology 2025; doi:10.1093/bjd/ljaf424.

Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan.

Shoji J, Ebihara N

Japanese journal of ophthalmology 2026; (70(1)):1-17 doi:10.1007/s10384-025-01299-9.

Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of current management and changing trends.

Akgun Z, Can GD, Selver OB

Indian journal of ophthalmology 2025; (73(12)):1711-1722 doi:10.4103/IJO.IJO_1119_25.

Air Pollution, Pollen, and Indoor Exposures in Allergic Conjunctivitis: A Systematic Review.

Martinez-Perez C, Oliveira AP

Life (Basel, Switzerland) 2026; (16(2)) doi:10.3390/life16020271.

Cytokine Levels and Clinical Characteristics in the Tear Fluid of Patients with Atopic Dermatitis and Atopic Keratoconjunctivitis.

Hansen PM, Utheim TP, Aass HCD, et al.

The ocular surface 2026; doi:10.1016/j.jtos.2026.02.010.